Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152682 | 0.80 | MAPT (0.40) | KMT2AALDH1A1MAPTPSMD14MEN1 | |
| SCHEMBL5227256 | 0.80 | MAPT (0.40) | KMT2AALDH1A1MAPTPSMD14MEN1 | |
| SCHEMBL1548578 | 0.80 | CA2 (0.44) | KMT2AALDH1A1MAPTPSMD14CYP2A6 | |
| Hydrochloric Acid SCHEMBL28225407 | 0.78 | MAPT (0.39) | KMT2AALDH1A1MAPTPSMD14MEN1 | |
| SCHEMBL7132351 | 0.75 | L3MBTL1 (0.46) | KMT2AALDH1A1L3MBTL1HTTTDP1 | |
| SCHEMBL6261093 | 0.75 | MAPT (0.52) | KMT2AALDH1A1MAPTPSMD14MEN1 | |
| SCHEMBL10979449 | 0.73 | KMT2A (0.38) | KMT2AALDH1A1MAPTMEN1CYP2A6 | |
| SCHEMBL5229246 | 0.72 | MEN1 (0.52) | KMT2AALDH1A1MAPTMEN1L3MBTL1 | |
| SCHEMBL23092462 | 0.72 | GAA (0.39) | KMT2AALDH1A1MAPTPSMD14MEN1 | |
| SCHEMBL7057572 | 0.72 | APP (0.66) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105237523-B | Pyrimidine derivatives and preparation method thereof, purposes | 深圳市博圣康生物科技有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-105237523-A | Pyrimidine derivatives, and preparation method and use thereof | SHENZHEN BIOSCIEN PHARMACEUTICALS CO LTD | 2016-01-13 | — | — | CN | claimed |
| CN-119899170-A | Fluorine-containing thiophene compound, preparation method thereof and electrolyte | 江苏华盛锂电材料股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4164622-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Icahn School of Medicine at Mount Sinai (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2004026881-A1 | MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003076437-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-6495683-B2 | HERPES VIRUS | PHARMACIA AND UPJOHN COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | KMT2A 578/4885ALDH1A1 2654/4885MAPT 4492/4885 |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK6, CDKL2 | KMT2A 634/4885ALDH1A1 2473/4885MAPT 3291/4885 |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IL4, ZC3HAV1 | KMT2A 897/4885ALDH1A1 1869/4885MAPT 3930/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | KMT2A 955/4885ALDH1A1 2021/4885MAPT 2434/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KMT2A 955/4885ALDH1A1 2021/4885MAPT 2434/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KMT2A 955/4885ALDH1A1 2021/4885MAPT 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.